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ABSTRACT
Although umbilical cord blood has been increasingly used as an alternative donor source to treat hematologic
malignancies, cord blood transplantation (CBT) is frequently complicated by graft failure and relapse of primary
diseases. Because persistence or increase of recipient-derived hematopoietic or malignant cells has pathogenic
import under these conditions, analysis of recipient-derived cells should be useful to understand the pathogen-
esis of graft failure and relapse of primary disease. Because most CBT involves human leukocyte antigen (HLA)-
mismatched transplantation, we developed a 9-color fluorescence activated cell sorter (FACS)-based method of
mixed chimerism (MC) analysis using anti-HLA antibodies to detect mismatched antigens (HLA-Flowmethod).
Among CD41 T cells, CD81 T cells, B cells, NK cells, monocytes, and granulocytes, donor- and recipient-
derived cells alike could be individually analyzed simultaneously in a rapid, quantitative and highly sensitiveman-
ner, making the HLA-Flow method very valuable in monitoring the engraftment process. In addition, this
method was also useful in monitoring recipient-derived cells with leukemia-specific phenotypes, both as mini-
mal residual disease (MRD) and as early harbingers of relapse. Leukemia relapse can be definitively diagnosed by
cytogenetic or PCR studies using recipient-derived cells sorted for leukemia markers. Multicolor HLA-fFlow
analysis and cell sorting in early diagnosis of graft failure and relapse was confirmed as valuable in 14 patients
who had received HLA-mismatched CBT.
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Analysis of donor-recipient mixed chimerism
(MC) after allogeneic stem cell transplantation has
become routine in confirming the engraftment of do-
nor-derived cells. Polymerase chain reaction-based
short tandem repeat analysis (STR-PCR) [1] and X/
Y chromosome analysis using fluorescence in situ hy-
bridization (X/Y-FISH) [2] after gender-mismatched
transplantation are the methods most commonly
used for mixed chimerism (MC) analysis. Persistence
of recipient-derived cells early after transplantation
or increases in their numbers are thought to be riskfactors for relapse of leukemia [3-5]. In fact, if immu-
nosuppression is discontinued or donor lymphocyte
infusions (DLI) are given after early identification of
increased numbers of recipient-derived cells, the
outcome of SCT is significantly improved [6,7]. Be-
cause lineage-specific analysis of MC is thought to be
important in understanding the pathogenesis of graft
failure and subsequent relapse of leukemia, several
research groups evaluated MC of individual leukocyte
subpopulations using magnetic cell separation or fluo-
rescence-activated cell sorting (FACS) techniques
followed by PCR-based analyses [8,9]. PCR- or693
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sensitive, and time consuming, especially in the case
of lineage-specific MC analysis.
During the last decade, the technologies support-
ing multicolor FACS analysis have been dramatically
developed [10,11]. This methodology is very useful
to investigate the pathogenic conditions of human dis-
eases by the simultaneous analysis of many phenotypes
and functions of cells [12,13]. If donor- and recipient-
derived cells have specific surface markers that are able
to be stained by fluorescence-conjugated antibodies,
respectively, chimerism analysis may be possibly
done by flow cytometry in a rapid, quantitative, and
highly sensitive manner.
The number of cord blood transplantations (CBTs)
has increased recently. Most CBTs are carried out with
human leukocyte antigen (HLA)-mismatched donor-
recipient combinations, especially in adult patients
[14-16]. If donor- and recipient-specific anti-HLA
antibodies, respectively, can stain donor- and recipi-
ent-specific HLAs, lineage-specific MC theoretically
can be analyzed by multicolor flow cytometry in the
setting of HLA-mismatched transplantation [10,11].
Serologic analysis of HLA was first established by
Paul I. Terasaki as a lymphocyte toxicity test using an-
tiserum from a multiparous woman that contained
anti-HLA polyclonal antibodies [17]. These poly-
clonal antibodies cannot be used for flow cytometric
analysis because of their low affinity and complicated
crossreactivity for HLAs [18]. Because the availability
of these anti-HLA polyclonal antibodies is limited and
it is difficult to maintain their quality, Terasaki et al.
established hybridomas to produce anti-HLA mono-clonal antibodies (mAbs) that can be used for
serologic analysis of HLA. These anti-HLA antibodies
are also useful for flow cytometric analysis [19,20].
To overcome the problems of current PCR- or
FISH-based methods for MC analysis, we have devel-
oped a flow cytometry-based method, using fluores-
cence-conjugated anti-HLA mAbs, of MC analysis
after HLA-mismatched transplantation. Here we
show that this HLA-Flow method is very useful for
analysis of lineage-specific MC after HLA-mis-
matched CBT.
RESULTS
Analysis of Recipient-Derived Cells Using the
HLA-Flow Method to Monitor Engraftment
Early after CBT
We analyzed lineage-specific MC in 9 patients
early after CBT (Table 1; unique patient numbers
[UPNs] 1 through 9). Figure 1A shows typical results
of peripheral blood MC analysis at week 2 after CBT
for mononuclear cells (PBMCs) and leukocyte sub-
populations (UPN 1). Lineage-specific MC could be
separately analyzed for CD41 T cells, CD81 T cells,
NK cells, monocytes, and granulocytes. The highest
frequency of recipient-derived cells existed in the
CD41 T cell subset (4.62% of total CD41 T cells).
In 7 patients, recipient-derived cells were consistently
observed in the CD31T cell subset before week 3 after
CBT (UPNs 1, 3-5, and 7-9). These patients showed
complete chimerism at week 4 after CBT (Figure 1B)
and all achieved donor-type engraftment successfully
(data not shown). Another patient (UPN2)maintainedTable 1. Patient Characteristics and Outcomes after Cord Blood Transplantation
Donor HLA Recipient HLA
UPN Disease Age A B A B Outcome
1 AML (M2) 50 2, 24 52, 62 2, 11 52, 67 Relapse (day 281), 2nd CBT (day 497)
2 MDS (RAEB) 41 2, 24 13, 61 2, 26 13, 61 CR (day 434)
3 MDS (Overt AML) 44 11, 26 61, 61 24, 26 7, 61 CR (day 592)
4 AML (M2) 41 2, 31 52, 61 2, 31 61, 62 Relapse (day 203), 2nd CBT (day 314)
5 AML (M0) 33 11, 24 7, 54 2, 24 7, 39 CR (day 137)
6 AML (M3) 50 2, 24 71, 61 1, 2 38, 61 Death (day 21, HHV6B encephalitis)
7 AML (M2) 52 2, 24 35, 67 11, 24 56, 67 CR (day 112)
8 AML (M2) 55 2, 2 51, 52 24, 24 51, 52 CR (day 105)
9 AML (M4Eo) 49 11, 11 62, 71 24, 24 62, 72 CR (day 71)
10 AML (M2) 49 2, 24 46, 52 2, 26 46, 52 CR (day 1,568)
11 MDS (RAEB-T) 35 24, 33 44, 52 26, 33 61, 44 CR (day 613)
12 AML (M4) 43 2, 24 46, 62 24, 31 46, 61 CR (day 938)
13 AML (M4) 45 2, 24 61, 62 2, 24 7, 61 CR (day 844)
14 MDS (Overt AML) 42 11, 33 55, 44 24, 33 55, 44 CR (day 1,569)
Conditioning regimen consists of TBI (12 Gy) 1 Ara-C 1 CY in all patients except 2 (TBI 1 Ara-C 1 Flu in UPNs 8 and 13). GVHD pro-
phylaxis consists of CsA 1 MTX in all patients except 1 (CsA 1 MMF in UPN 8). Subtype of HLA-A and B specifically recognized by
anti-HLA antibodies are underlined. Both engraftment and minimal residual disease were monitored in UPN 1-4. Only engraftment was
monitored in UPN 5-9. Only minimal residual disease was monitored in UPN 10-14. Outcomes were confirmed on August 10, 2007.
UPN indicates unique patient number; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; RAEB, refractory anemia with
excess of blasts; RAEB-T, RAEB in transplantation; TBI, total body irradiation; Ara-C, cytosine arabinoside; G, granulocyte colony-stim-
ulation factor; CY, cyclophosphamide; Flu, fludarabin; CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil.
Recipient-Derived Cells after Cord Blood Transplantation 695Figure 1.MC analysis early after CBT in 9 patients. (A) In UPN 1, peripheral blood mononuclear cells were stained with an antibody combi-
nation of FITC-HLA-A24 (donor-specific), biotin-HLA-A11 (recipient-specific), PerCP-Cy5.5-CD8, PE-Cy7-CD3, APC-CD56, APC-Cy7-
CD19, Pacific Blue-CD4, and Pacific Orange-CD14 followed by staining with SA-PE. Cells were stained with PI just before FACS analysis.
After gating overall PBMCs, the lymphocyte subpopulation and the monocyte subpopulation on the FSC-SSC plot, PI-positive dead cells de-
tected by PE-TR (610/20) detector were gated out from each subpopulation. In the lymphocyte fraction, CD41 T cells (CD31CD41 cells),
CD81 T cells (CD31CD81 cells), B cells (CD32CD191 cells) and NK cells (CD32CD192CD561 cells) were gated using lineage markers
CD3, CD4, CD8, CD19, and CD56. Monocytes were gated using lineage marker CD14. MC was analyzed using HLA-A24 and HLA-A11
for PBMCs overall (upper left), CD41T cells (upper middle), CD81 T cells (upper right), NK cells (lower left), and monocytes (lower middle).
Granulocyte fractions isolated from peripheral blood were stained with an antibody combination of FITC-HLA-A24, biotin-HLA-A11, and
APC-CD11b followed by staining with SA-PE. Cells were stained with PI just before FACS analysis. After the granulocyte fraction was gated
on the FSC-SSC plot, PI-marked dead cells were gated out. Granulocytes were gated using lineage marker CD11b. MC was analyzed in this
subpopulation using HLA-A24 and HLA-A11 (lower right). (B) In UPN 1 to 9, peripheral blood (10 mL) was drawn at week 1, 2, 3, and 4 after
CBT and FACS-based MC analysis was performed, using 5 mL of blood (percentage of recipient-derived PBMCs isolated by centrifugation on
Ficoll-Paque). In UPN 2 (), numbers of recipient-derived cells started to increase after week 3 and persisted at 10% of total PBMCs. UPN 6
() died on day 21 because of human herpesvirus 6B encephalitis and multiple organ failure.
696 N. Watanabe et al.Figure 2. MC analysis of peripheral blood cells early after CBT in UPN 2. (A) In UPN 2, mononuclear cells and granulocytes isolated from
peripheral blood were stained with the antibody combinations described in Figure 1 (excepting biotin-HLA-A11, replaced by biotin-HLA-
A26). Total mononuclear cell MC results at weeks 1, 2, 3, 6, and 10 are shown. (B) CD41 T cell, CD81 T cell, NK-cell, monocyte, and gran-
ulocyte MC results at week 3 after CBT are shown.MC early after CBT, and yet another (UPN 6) died on
day 21 (Figure 1B).
In both UPN 2 and UPN 1, recipient-derived cells
decreased to 1.5% of PBMCs at week 2 after CBT.
Recipient-derived cells, however, started to increase at
week3 inUPN2andpersisted at10%of total PBMCs
for the next 3 weeks (Figure 1B and Figure 2A); these
increased recipient-derived cells were mainly observed
in the monocyte and granulocyte fractions, but not in
the T cell fractions (Figure 2B). Significant numbers
of recipient-derived cells in the CD341CD45dim (he-
matopoietic stem/progenitor) fraction (Figure 3B,
left), in addition to those in the CD342CD451 (mature
cell) fraction (Figure 3B, right), were detected in bone
marrow at week 7 after CBT (Figure 3C, left). Because
recipient-derived cells were persistently observed in
serial MC analyses, from week 4 after CBT we rapidly
reduced CsA doses, resulting in a quick decrease in re-
cipient-derived cells in the peripheral blood around
week 6 to week 10 after CBT (Figure 2A). Recipient-
derived cells also dramatically decreased in bone
marrow at week 20 (data not shown). The percentages
of recipient-derived cells among all white blood cells
were also determined by STR-PCR in 5 patients. Per-
centages of recipient-derived cells among all mononu-
clear cells were similar when determined by the flow
cytometry-based method (Table 2).
Analysis of Recipient-Derived Cells for
Leukemia Cell Markers to Monitor Minimal
Residual Disease (MRD)
We analyzedMC in bonemarrow samples tomon-
itor minimal residual disease (MRD) in 9 patients(UPNs 1-4 and 10-14). Seven patients maintained
complete remission at last follow-up (Table 1).
UPNs 1 and 4 showed relapse of leukemia on day
281 and day 203, respectively. In UPN 1, we serially
analyzed recipient-derived cells in bone marrow 5
months and more after CBT. This patient underwent
CBT for acute myelogenous leukemia (AML)-M2
with a chromosomal translocation between chromo-
some 8 and chromosome 21: t(8;21). The phenotype
of leukemia cells was CD341CD45dimHLA-
DR1CD561. AML1/ETO served as a leukemia-
specific chimeric gene marker for this patient. After
gating of CD341CD45dim cells, having the phenotype
of either normal hematopoietic stem/progenitor cells
or leukemia cells [21-23], on the CD34-CD45 plot
(Figure 4A-G2), MC in this subpopulation was
analyzed in terms of the expression levels of HLA-
A24 as a marker of the donor and of HLA-A11 as
a marker of the recipient. On day 281, frequencies of
recipient-derived cells in the CD341CD45dim fraction
were clearly increased (5.71% of the CD341CD45dim
fraction; Figure 4B, middle) compared with those on
day 159 (0.16%; Figure 4B, left). In contrast, recipi-
ent-derived cells were not detected on day 281, partic-
ularly among CD342CD451 cells, having the
phenotype of mature blood cells (Figure 4C-G7), or
in peripheral blood (data not shown). On day 320,
recipient-derived cells had risen to more than half of
CD341CD45dim cells (Figure 4B, right). In the
CD341CD45dim fraction, donor-derived cells
revealed an HLA-DR1CD562 phenotype and recipi-
ent-derived cells revealed an HLA-DR1CD561
phenotype, the same as that of leukemia cells
Recipient-Derived Cells after Cord Blood Transplantation 697Figure 3.MC analysis of bone marrow cells at week 7 after CBT in UPN 2. (A) In UPN 2, mononuclear cells isolated from aspirated bone mar-
row at week 7 were stained with an antibody combination of FITC-HLA-A24 (donor-specific), biotin-HLA-A26 (recipient-specific), PerCP-
Cy5.5-HLA-DR, PE-Cy7-CD33, APC-CD34, APC-Cy7-CD56, Alexa Fluor 405-CD45, and Pacific Orange-CD14 followed by staining
with SA-PE. Cells were stained with PI just before FACS analysis. After gating for mononuclear cells not stained by PI (left), bone marrow cells
were analyzed with a combination of anti-CD34 and anti-CD45 (right). On this CD34-CD45 plot, 8 distinct subpopulations were observed (ten-
tative gate 1 [G1] to G8, reflecting different kinds of cells). Because these 8 subpopulations had different levels of autofluorescence and HLA
expression, positions of donor- and recipient-derived cells on the HLA-A24 versus HLA-A26 plot were different in each subpopulation. (B)
For example, the distribution of recipient-derived cells in G2 (CD341CD45dim fraction, left; hematopoietic/progenitor cells) differed from
that in G8 (CD342CD451 fraction, right; mature white blood cells. (C) To elucidate overall distributions of donor- and recipient-derived cells,
MC was first analyzed separately in G1 to G8. Donor-derived cells (light green dots) and recipient-derived cells (blue dots) were then plotted on
the CD34 versus CD45 plot (left) or the HLA-A24 versus HLA-A26 plot (right). On the HLA-A24 versus HLA-A26 plot (right), the distribu-
tions of donor- and recipient-derived cells overlapped, precluding direct gating on this plot of donor- and recipient-derived cells among total
bone marrow mononuclear cells.(Figure 4D). Finally, we sorted the donor- and recipi-
ent-derived CD341CD45dim cells on day 320 to inves-
tigate whether recipient-derived CD341CD45dim
cells were leukemia cells or not. After fixation of sortedcells on glass slides, the AML1/ETO chimeric gene
was analyzed using FISH probes (cf. Methods). Recip-
ient-derived CD341CD45dim cells but not donor-
derived ones showed AML1/ETO fusion signals
698 N. Watanabe et al.(Figure 4E, left, and 4E, right, respectively). In UPN
4, we detected 12.1% of recipient-derived cells among
the CD341CD45dim fraction on day 182. Leukemia
relapse was subsequently diagnosed, on day 203, by
morphologic examination (data not shown).
DISCUSSION
Using this FACS-based method, we could not only
monitor the engraftment process, but also investigate
the mechanism of engraftment failure. We observed
2 different types of kinetics in engraftment of cord
blood-derived cells in this study. Seven patients
(UPN 1, 3-5, 7-9) showed successful engraftment
resulting in complete chimerism at week 4 after
CBT. In contrast, UPN 2 showed persistent MC for
more than 6 weeks after CBT. Recipient-derived cells
in the peripheral blood were detected in the monocyte
and the granulocyte fractions but not in the CD41 and
CD81 T-cell fractions in this patient (Figure 2B).
Because granulocytes and monocytes are terminally
differentiated cells with a short half-life and do not
proliferate in the periphery, we speculated that the
recipient-derived granulocyte-monocyte progenitors,
that is, colony-forming units of granulocytes and
monocytes (CFU-GM), existed in bone marrow and
supplied mature granulocytes and monocytes to
peripheral blood. MC analysis of bone marrow cells
Table 2. Percentage of Recipient-Derived Cells of Total Peripheral Blood
Cells Determined by the HLA-Flow Method and STR-PCR Method
Time after CBT (Weeks)
Pt# Method of MC Analysis 1 2 3 4
2 HLA-Flow method 43.3 1.46 14.4 13.2
STR-PCR method 64.6 0.0 24.3 11.9
3 HLA-Flow method 44.4 1.31 0.023 NT
STR-PCR method 39.4 0.0 0.0 NT
4 HLA-Flow method * * 0.046 NT
STR-PCR method NT NT 0.0 NT
5 HLA-Flow method 38.2 2.07 0.075 0.00
STR-PCR method 64.5 10.5 0.0 0.0
6 HLA-Flow method 4.18 0.25 †
STR-PCR method 16.2 0.0 †
At the time point as shown in the above, 10 mL peripheral blood was
drawn and MC analysis was done by the flow cytometry-based
method (HLA-Flowmethod) using 5 mL of blood. In these 5 pa-
tients, another 5 mL was used for MC analysis by the STR-PCR
method. The FACS-based method shows the percentage of
recipient-derived cells of total mononuclear cells isolated by cen-
trifugation on Ficoll-Paque. The STR-PCR method shows the
percentage of recipient cells of total white blood cells in which
peripheral blood was lyzed and genomic DNA was extracted
from white blood cells.
NT indicates not tested; Pt, patient; CBT, cord blood transplanta-
tion.
*MC could not be analyze, because cells number from samples were
extremely low.
†Patient 6 died on day 21 because of human herpesvirus 6B
(HHV6B) encephalitis and multiple organ failure.clearly showed recipient-derived CD341CD45dim
cells (Figure 3C, left), which should include progeni-
tors containing granulocyte-monocyte lineages [24].
In this patient, we tapered cyclosporine A (CsA) to
eliminate residual recipient-derived cells. Because
MC analysis results were available within 1.5 hours
after blood or tissue sampling, HLA-Flow was very
helpful in titrating CsA doses.
In this study, we compared HLA-Flow against
STR-PCR in detection of MC. The results were
comparable as shown in Table 2, but our FACS-based
analysis had several advantages. We could obtain
results thereby more quickly (\1.5 hours) than with
STR-PCR, and with a logarithmic increase in sensitiv-
ity (0.1% versus 5%). We could also obtain lineage-
specific MC data via HLA-Flow.
Normal hematopoietic stem/progenitor cells21
and myeloid and B-lineage leukemia cells belong to
the CD45dim fraction [22,23], and most of them also
express CD34 antigen. Mesenchymal cells (which are
not replaced with donor-derived cells) are
CD342CD452CD441CD731CD901CD1051 [25].
Therefore, to monitor residual leukemia cells cor-
rectly, the chimerism in the CD341CD45dim fraction
had to be analyzed, on the basis of a CD34-CD45
plot, separately from the CD342CD452 fraction that
contained recipient-derived mesenchymal cells. In
UPN 1, we serially analyzed bone marrow cells to
monitor MRD. On day 159, using FISH and RT-
PCR, we did not detect expression of the AML1/
ETO chimeric gene (a tumor-specific marker for this
patient). Nor did we detect a significant number of
recipient-derived cells among CD341CD45dim cells
(0.16% of total CD341CD45dim cells) by HLA-
Flow. Although the relapse of leukemia could not be
confirmed on day 281 by microscopic examination
because leukemia cell frequencies were low (0.37%
of total mononuclear cells), HLA-Flow could clearly
show a significant number of recipient-derived cells
in the CD341CD45dim fraction (Figure 4B, middle).
Although FISH and PCR analysis also showed an in-
crease in AML1/ETO expression, it took 7 days to
obtain these results. Sorting of donor- and recipient-
derived CD341CD45dim cells followed by FISH anal-
ysis clearly showed that only the recipient-derived
expressed the leukemia-specific AML1/ETO fusion
signal; the donor-derived did not. This result demon-
strated that HLA-Flow, especially the contribution
made by sorting, is very useful in early detection and
confirmation of relapse of leukemia.
In this case, leukemia cells expressed CD34,
CD56, and HLA-DR in the study at the time of
diagnosis. We also detected donor-derived normal
progenitor cells and recipient-derived leukemia cells
in the CD341CD45dim fraction (Figure 4D) as
HLA-DR1CD562 phenotypes (green dots) and
HLA-DR1CD561 phenotypes (red dots), respectively.
Recipient-Derived Cells after Cord Blood Transplantation 699Figure 4. Correlation of results fromMC analysis with leukemia cell-associated aberrant antigen expression and leukemia-specific gene expres-
sion in the CD341CD45dim fraction of bonemarrow cells in UNP 1. (A) InUPN1, mononuclear cells isolated from aspirated bonemarrowwere
stained with the antibody combinations described in Figure 3 (excepting biotin-HLA-A26, replaced by biotin-HLA-A11). Cells were stained
with PI just before FACS analysis. After gating for mononuclear cells not stained by PI, bone marrow cells were analyzed with a combination
of anti-CD34 and -CD45. On this CD34-CD45 plot, 7 distinct subpopulations (G1 to G7) were observed. (B) MC was analyzed in
CD341CD45dim cells (A-G2) using anti-HLA antibodies on days 159, 281, and 320. (C) On day 281, the distributions of donor- and recipi-
ent-derived cells in G1-G7 were plotted on the CD34-CD45 configuration. (D) On day 320, expression of cell surface markers HLA-DR
and CD56 on donor-derived and recipient-derived CD341CD45dim cells was analyzed (HLA-DR versus CD56 plot: donor-derived
CD341CD45dim cells, green dot; recipient-derived ones, red dots). (E) Recipient-derived CD341CD45dim cells and donor-derived ones were
sorted separately and analyzed for AML1/ETO fusion signals using FISH (left, recipient-derived CD341CD45dim cells; right, donor-derived
ones).We believe that this approach, using antibodies against
leukemia cells’ aberrant antigens, can be used to detect
malignant cells even when tumor-specific genetic
markers are unavailable.
Schumm et al. [26] have recently reported that a 4-
color flow cytometry-based method using anti-HLA
antibodies was useful for determination of chimerism
and MRD. In analyzing MC they stained only for do-
nor-specific HLAs. In our experience, however, clear
separation of donor- and recipient-derived cells was
difficult when using only a single anti-HLA antibody
with a few lineage markers because of several technical
problems; nonspecific staining, variable autofluores-
cence and HLA expression among different cell
populations, downregulation of cell surface HLAmol-
ecules, etc. In addition, because peripheral blood
contains only a few cells early after SCT, to analyze
MC in many lineage-specific subsets was very difficult.
We therefore introduced a 9-color FACS-based
system to permit simultaneous analysis, using just
a 5-mL blood sample, of both donor and recipient
HLA, 6 additional lineage markers, and dead cells,
even early after CBT when leukocyte counts are low.Although the distributions of donor- and recipient-
derived cells often overlapped on the direct donor
HLA versus recipient HLA plot because of some tech-
nical problems as mentioned above, we could accu-
rately elucidate MC in appropriate subpopulations as
shown in Figure 3A and 3B. In addition, we used
FACS-based sorting to permit further analysis of
sorted cells for definitive diagnosis, as described.
More than 20 fluorescence-labeled anti-HLA-A
and B antibodies are commercially available from
One Lambda Inc. (Canoga Park, CA) and AbD Serotec
Ltd. (Kidlington, UK). We investigated the diversity
of donor-recipient HLA mismatches in Japanese
CBT cohort and found that .45% of CBT cases
were covered by HLA-Flow method with these com-
mercial antibodies. Although 9-color flow cytometry
is still complicated technique, commercial availability
of multicolor FACS machine with autocompensation
software and new fluorescence-labeled antibodies
make this technique easier. Therefore, applications
of this HLA-Flow method is not restricted to a few
cases in sophisticated flow cytometry laboratories.
Our data indicate that to monitor lineage-specific
700 N. Watanabe et al.MCafterHLA-mismatchedCBT, using a rapid, quan-
titative, and highly sensitive FACS-based method, can
contribute substantially to clinical management by
permitting early diagnosis of graft failure as well as
of leukemia relapse.
MATERIALS AND METHODS
Patient Characteristics
We analyzed 14 patients after CBT. Their clinical char-
acteristics are summarized in Table 1. Patients with AML
and myelodysplastic syndrome (MDS) underwent CBT at
The Institute of Medical Science, The University of Tokyo
(IMSUT), between June 2002 and May 2007. Twelve pa-
tients underwent a 12-Gy total body irradiation (TBI)-
containing myeloablative pretransplantation conditioning
regimen of TBI 1 recombinant human granulocyte col-
ony-stimulating factor (G-CSF) combined with cytosine
arabinoside (Ara-C) 1 cyclophosphamide [16]. One patient
(UPN13) underwent a 12-GyTBI-containingmyeloablative
pretransplantation conditioning regimen of TBI 1 G-CSF
combined with Ara-C 1 fludarabine (Flu). They received
a standard CsA and methotrexate (MTX) combination as
GVHD prophylaxis. One patient (UPN 8) underwent a 4-
Gy TBI-containing nonmyeloablative pretransplantation
conditioning regimen of TBI 1 G-CSF combined with
Ara-C1 Flu. He received a CsA and mycophenolate mofetil
(MMF) combination as GVHD prophylaxis. The institu-
tional review board of IMSUT approved the clinical proto-
col, and written informed consent was obtained from all
patients in accordance with the Declaration of Helsinki.
Cell Preparations and Staining
For monitoring of engraftment, 10 mL of peripheral
blood was collected at 1, 2, 3, and 4 weeks after CBT in 9 pa-
tients (Table 1; UPN 1-9). Additional samples were collected
when MC continued. For monitoring MRD, peripheral
blood specimens and bone marrow aspirates were serially
collected 5 months and more after CBT in 9 patients
(UPN 1 to 4 and 10 to 14 in Table 1). Mononuclear cells
were isolated by centrifugation of peripheral blood and
bone-marrow aspirate specimens on Ficoll-Paque (Sigma,
St. Louis, MO). Granulocytes were isolated from buffy
coat after centrifugation of peripheral blood on Ficoll-Paque
followed by lysis using ammonium chloride lysing buffer.
The isolated cells were washed once with ice-cold phos-
phate-buffered saline (PBS, Sigma), suspended in a small vol-
ume of PBS containing 5% mouse serum (Dako, Glostrup,
Denmark) to block nonspecific binding of fluorescence-
labeled antibodies to immunoglobulin Fc receptors, and
kept on ice until staining.
For monitoring of engraftment, anti-HLA mAbs in
combination with lineage-specificmAbs were used to analyze
the lineage-specific dynamics of recipient-derived cells. For
example, in UPN 1, mononuclear cells were stained using
the combination of fluorescein isothiocyanate (FITC)-
conjugated anti-HLA-A24 antibody (FITC-HLA-A24,
donor-specific), biotin-HLA-A11 (recipient-specific),
Peridinin chlorophyll protein (PerCP)-Cy5.5-CD8, phyco-
erythrin (PE)-Cy7-CD3, allophycocyanin (APC)-CD56,
APC-Cy7-CD19, Pacific Blue-CD4, and Pacific Orange-CD14 followed by staining with streptavidin (SA)-PE.
Granulocytes were stained using the combination of
FITC-HLA-A24, biotin-HLA-A11, and APC-CD11b fol-
lowed by staining with SA-PE. When monitoring MRD,
anti-HLA mAbs combined with mAbs against antigens
expressed on leukemia cells were used to detect recipient-
derived cells expressing leukemia markers. For example, in
UPN 1, mononuclear cells were stained using the antibody
combination of FITC-HLA-A24, biotin-HLA-A11,
PerCP-Cy5.5-HLA-DR, PE-Cy7-CD33, APC-CD34,
APC-Cy7-CD56, Alexa Fluor 405-CD45, and Pacific Or-
ange-CD14 followed by staining with SA-PE. Samples
were stained with fluorescence-conjugated antibodies for
20 minutes on ice, washed twice with ice-cold PBS, and
suspended in a small volume of ice-cold PBS.
Anti-HLA mAbs specific for donor and recipient HLAs
in all patients are summarized in Table 1. All anti-HLA an-
tibodies were purchased from One Lambda. Pacific Orange-
CD14 and Alexa Fluor 405-CD45 were purchased from
CALTAG-Invitrogen (Carlsbad, CA). Other antibodies,
SA-PE and SA-APCwere purchased fromBecton-Dickinson
(BD) pharmingen (San Jose, CA).
FACS Analysis
Propidium iodide (PI; 1 mg/mL; Sigma) was added to
samples to stain dead cells just before FACS analysis; dead
cells were detected using a photo multiplier tube (PMT)
with a 610/20-nm bandpass filter (detector for PE-Texas
Red conjugates). BD FACS Aria (BD Immunocytometry
Systems, San Jose, CA) was used for all multicolor FACS
analysis and sorting. Flow cytometry standard data were an-
alyzed using FlowJo software (Treestar, San Carlos, CA).
The gating procedures used to identify subsets in peripheral
blood and bonemarrow are explained respectively in Figure 1
and Figure 3.
STR-PCR
MC was also analyzed using STR-PCR at SRL (Tachi-
kawa, Tokyo, Japan), to monitor engraftment in 5 patients
after CBT. Peripheral blood from the recipient and cord
blood were obtained before CBT, and DNA was extracted
from these samples. Using this DNA for templates, PCR
was carried out with 10 fluorescence-labeled STR primers
(AmpFlSTR SGM plus kit, Applied Biosystems, Foster
City, CA) to find markers distinguishing donors from recip-
ients. Peripheral blood was collected at defined times after
CBT. Samples underwent FACS-based MC analysis
followed by DNA extraction. PCR products using donor
DNA and recipient DNA obtained before and after CBT
were analyzed using a capillary electrophoresis ABI
PRISM310 Genetic Analyzer and GeneScan and Geno-
Typer software (all Applied Biosystems). The sensitivity of
this analysis was 5% [1].
AML1/ETO-FISH
In UPN 1, who had AML-M2, the AML1/ETO chime-
ric gene was analyzed by FISH at SRL. After separating
donor-derived from recipient-derived CD341CD45dim frac-
tions by FACS, cytospin samples were fixed on slide glasses
and hybridized with fluorescence-labeled AML1 and ETO
DNA probes (AML1/ETO Dual Color, Dual Fusion
Recipient-Derived Cells after Cord Blood Transplantation 701Translocation Probe, Cancer Genetics, Abbott Molecular,
Des Plaines, IL). In all cases, 100 nuclei were scored per slide
to reach 5  1022 sensitivity.
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